260 related articles for article (PubMed ID: 34049187)
1. Precision medicine in breast cancer: From clinical trials to clinical practice.
Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC
Ann Oncol; 2019 Mar; 30(3):365-373. PubMed ID: 30715161
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
5. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
6. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
[TBL] [Abstract][Full Text] [Related]
10. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Chao TC; Lai JI; Tseng LM; Huang CC
Breast Cancer; 2024 Mar; 31(2):217-227. PubMed ID: 38070067
[TBL] [Abstract][Full Text] [Related]
11. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
[TBL] [Abstract][Full Text] [Related]
12. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
13. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Aftimos P; Oliveira M; Irrthum A; Fumagalli D; Sotiriou C; Gal-Yam EN; Robson ME; Ndozeng J; Di Leo A; Ciruelos EM; de Azambuja E; Viale G; Scheepers ED; Curigliano G; Bliss JM; Reis-Filho JS; Colleoni M; Balic M; Cardoso F; Albanell J; Duhem C; Marreaud S; Romagnoli D; Rojas B; Gombos A; Wildiers H; Guerrero-Zotano A; Hall P; Bonetti A; Larsson KF; Degiorgis M; Khodaverdi S; Greil R; Sverrisdóttir Á; Paoli M; Seyll E; Loibl S; Linderholm B; Zoppoli G; Davidson NE; Johannsson OT; Bedard PL; Loi S; Knox S; Cameron DA; Harbeck N; Montoya ML; Brandão M; Vingiani A; Caballero C; Hilbers FS; Yates LR; Benelli M; Venet D; Piccart MJ
Cancer Discov; 2021 Nov; 11(11):2796-2811. PubMed ID: 34183353
[TBL] [Abstract][Full Text] [Related]
14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
15. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
16. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E; Annaratone L; Bellomo SE; Ferrero G; Gagliardi A; Bragoni A; Grassini D; Guarrera S; Parlato C; Casorzo L; Panero M; Sarotto I; Giordano S; Cereda M; Montemurro F; Ponzone R; Crosetto N; Naccarati A; Sapino A; Marchiò C
Genome Med; 2022 Aug; 14(1):98. PubMed ID: 36038884
[TBL] [Abstract][Full Text] [Related]
18. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Heeke AL; Xiu J; Elliott A; Korn WM; Lynce F; Pohlmann PR; Isaacs C; Swain SM; Vidal G; Schwartzberg LS; Tan AR
Breast Cancer Res Treat; 2020 Nov; 184(2):265-275. PubMed ID: 32776290
[TBL] [Abstract][Full Text] [Related]
19. Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy.
Raza M; Kumar N; Nair U; Luthra G; Bhattacharyya U; Jayasundar S; Jayasundar R; Sehrawat S
Mol Cell Biochem; 2021 Sep; 476(9):3271-3284. PubMed ID: 33886058
[TBL] [Abstract][Full Text] [Related]
20. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
